We would like to invite you to participate in the 9th Inhibitors of Protein Kinases Conference joined with the second meeting “Challenges in Molecular Biology, Biophysics, and Biomedicine“, which will be held 17th -21st of September, 2017,Warsaw, Poland. The preliminary list of invited speakers is attached at the end of the letter.
Protein and lipid kinases stand in the center spotlight of academic and industrial research. The launched drugs Gefitinib, Erlotinib, and Gleevec have already helped to save thousands of lives by inhibiting specific kinase leading to inhibition of cancer growth.
Protein phosphorylation is the most important pathway for regulation of protein function in living cells. It is involved in the switching of cellular activities from one state to another and, in this way, regulates gene expression, cellular proliferation, and cell differentation. It is the major mechanism by which cells respond to extracellular signals, such as hormones and growth factors, and controls all events in the various stages of the cell cycle, as well as the response of the cell to environmental and nutritional stresses. Besides cancer, the inhibition of kinases may be the key to treating other diseases, including neurological and autoimmune diseases. Over the last 18 years biannual IPK in Warsaw organized and later mentored by the late Prof. David Shugar brought together the top kinase international researchers from academia and industry. We plan to build on the success of the previous meetings and broaden the topics to include current trend in kinase inhibition. As we have done in the past, we assembled top researchers to serve as a magnet for growing the meeting even more.